IMVT
Price
$16.22
Change
+$0.55 (+3.51%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
2.73B
35 days until earnings call
MRUS
Price
$68.89
Change
+$0.79 (+1.16%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
5.15B
34 days until earnings call
Interact to see
Advertisement

IMVT vs MRUS

Header iconIMVT vs MRUS Comparison
Open Charts IMVT vs MRUSBanner chart's image
Immunovant
Price$16.22
Change+$0.55 (+3.51%)
Volume$23.54K
Capitalization2.73B
Merus
Price$68.89
Change+$0.79 (+1.16%)
Volume$17.03K
Capitalization5.15B
IMVT vs MRUS Comparison Chart in %
Loading...
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMVT vs. MRUS commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Buy and MRUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (IMVT: $16.22 vs. MRUS: $68.89)
Brand notoriety: IMVT and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMVT: 82% vs. MRUS: 42%
Market capitalization -- IMVT: $2.73B vs. MRUS: $5.15B
IMVT [@Biotechnology] is valued at $2.73B. MRUS’s [@Biotechnology] market capitalization is $5.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMVT’s FA Score shows that 0 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • IMVT’s FA Score: 0 green, 5 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, MRUS is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMVT’s TA Score shows that 3 TA indicator(s) are bullish while MRUS’s TA Score has 2 bullish TA indicator(s).

  • IMVT’s TA Score: 3 bullish, 5 bearish.
  • MRUS’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than MRUS.

Price Growth

IMVT (@Biotechnology) experienced а +9.74% price change this week, while MRUS (@Biotechnology) price change was +0.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

IMVT is expected to report earnings on Oct 31, 2025.

MRUS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($5.15B) has a higher market cap than IMVT($2.73B). MRUS YTD gains are higher at: 63.829 vs. IMVT (-36.738). MRUS has higher annual earnings (EBITDA): -347.56M vs. IMVT (-470.69M). MRUS has more cash in the bank: 710M vs. IMVT (599M). IMVT has less debt than MRUS: IMVT (98K) vs MRUS (11M). MRUS has higher revenues than IMVT: MRUS (56.2M) vs IMVT (0).
IMVTMRUSIMVT / MRUS
Capitalization2.73B5.15B53%
EBITDA-470.69M-347.56M135%
Gain YTD-36.73863.829-58%
P/E RatioN/AN/A-
Revenue056.2M-
Total Cash599M710M84%
Total Debt98K11M1%
FUNDAMENTALS RATINGS
IMVT vs MRUS: Fundamental Ratings
IMVT
MRUS
OUTLOOK RATING
1..100
7270
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
10018
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6341
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (40) in the null industry is in the same range as MRUS (54) in the Biotechnology industry. This means that IMVT’s stock grew similarly to MRUS’s over the last 12 months.

MRUS's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that MRUS’s stock grew significantly faster than IMVT’s over the last 12 months.

MRUS's SMR Rating (98) in the Biotechnology industry is in the same range as IMVT (98) in the null industry. This means that MRUS’s stock grew similarly to IMVT’s over the last 12 months.

MRUS's Price Growth Rating (41) in the Biotechnology industry is in the same range as IMVT (63) in the null industry. This means that MRUS’s stock grew similarly to IMVT’s over the last 12 months.

MRUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMVT (100) in the null industry. This means that MRUS’s stock grew similarly to IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMVTMRUS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 11 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
IMVT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLERX14.18N/A
N/A
GS Energy Infrastructure Fd R Shares
BSGIX15.70N/A
N/A
Baird Small/Mid Cap Growth Institutional
FFXFX92.51N/A
N/A
American Funds Fundamental Invs 529-F-2
JDWNX127.03N/A
N/A
Janus Henderson Global Research N
JACEX19.70N/A
N/A
JHancock Mid Cap Growth R6

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
+1.36%
ROIV - IMVT
59%
Loosely correlated
+1.77%
IDYA - IMVT
56%
Loosely correlated
+0.08%
OCUL - IMVT
55%
Loosely correlated
-2.55%
NUVL - IMVT
55%
Loosely correlated
-2.54%
DNLI - IMVT
53%
Loosely correlated
-0.37%
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with NUVL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+1.16%
NUVL - MRUS
54%
Loosely correlated
+4.99%
CGON - MRUS
51%
Loosely correlated
+3.02%
RVMD - MRUS
49%
Loosely correlated
+3.36%
IMVT - MRUS
49%
Loosely correlated
+3.51%
IDYA - MRUS
48%
Loosely correlated
+4.52%
More